Category: Finance
-
Organ Chip Devices to Model for Radiation Sickness
The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness.
-
Start-Up Adapts Crispr for Molecular Detection, Raises $40M
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler.
-
Infographic – Q3 Life Science Venture Funds Tick Up
Venture investments in U.S. life science and biotechnology start-ups in the third quarter of 2023 rose from the previous two quarters to reach pre-pandemic levels.
-
Longevity Science Group Spins-Off Biotech Start-Up
An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company.
-
FDA Funds Study of Real World Data for Biosimilars
A group of managed care organizations is examining the value of real world data from Europe and the U.S. to help FDA review alternative biologic drugs.
-
Neuro Disease Biotech Gains $61M in Early Funds
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round.
-
Infographic – Global Q3 Venture Funding Levels Off
Global venture investment dollars in the third quarter of 2023 rose somewhat from the previous quarter, but remained at about the same level for the past 12 months.
-
NIH Funds Antibody Discovery for Difficult Protein Targets
A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers.
-
Biomanufacturing Company Gains $9.5M in Early Funds
A company offering a biomanufacturing process it says is more efficient and scalable than conventional bio-production methods is raising $9.5 million in its first venture round.
-
Industry-Academic Center to Boost Rare Disease Therapies
An alliance of academic labs and venture investors is starting a new research enterprise to speed development of treatments for rare diseases in the U.S. and U.K.